Skip to main content

Parkinson's Disease Licensing Deal Benchmarks

Median Upfront
$357M
Range: $178M - $590M
Total Deal Value
$3.1B
Range: $1.9B - $4.4B
Royalty Rate
12.5% - 19.9%
Tiered up to 23.9%
Dev Milestones
$911M
Range: $559M - $1.2B
Model Your Deal

Market Analysis

Parkinson's disease licensing is experiencing heightened activity as disease-modifying candidates advance through Phase 2 clinical trials. Small molecule PD deals carry a median total deal value of $3.1B, with upfront payments between $178M and $590M. The shift from symptomatic dopaminergic treatments to disease-modifying alpha-synuclein and LRRK2-targeted therapies is reshaping deal economics.

PD deal structures are characterized by substantial development milestones averaging $911M, reflecting the challenging clinical endpoints (MDS-UPDRS) and longer trial durations in neurodegenerative disease. Regulatory milestones of $994M and commercial milestones of $856M round out the typical deal architecture.

Royalty rates for Parkinson's deals range from 12.5% to 19.9% at the base tier, with escalation to 23.9%. Disease-modifying therapies with biomarker-supported evidence of slowing progression command significant premiums over symptomatic treatments. The competitive landscape between GLP-1 agonists repurposed for PD, alpha-synuclein antibodies, and gene therapies creates a dynamic deal environment.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How are Parkinson's disease deal structures evolving?
PD deal structures are shifting toward disease-modifying mechanisms with higher total deal values. Phase 2 disease-modifying PD assets command $3.1B median total deal value versus substantially lower values for symptomatic-only programs. Biomarker endpoints (alpha-synuclein seeding assays, DAT-SPECT imaging) are increasingly used as milestone triggers.
What is the deal landscape for alpha-synuclein targeted therapies?
Alpha-synuclein therapeutics represent the largest category of PD licensing deals. Both active and passive immunotherapy approaches are actively transacted, with antisense oligonucleotides and small molecule aggregation inhibitors emerging as newer modalities. Clinical failures of first-generation alpha-synuclein antibodies have not dampened deal activity but have shifted valuations toward genetically validated patient subpopulations (GBA1, LRRK2 carriers).
How competitive is the neurodegenerative disease deal space?
The neurodegenerative deal space is highly competitive, with Alzheimer's and Parkinson's representing the two largest indication categories. PD deals benefit from a clearer biomarker framework than many other neurodegenerative indications, supporting more structured milestone agreements. Cross-indication potential (e.g., alpha-synuclein in Lewy body dementia) adds significant option value to PD-focused deals.

Related Benchmarks

Alzheimer's Deal Benchmarks

View

Neurology & CNS Deal Overview

View

Gene Therapy Deals

View

Small Molecule Deals

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating